Mycophenolate in dermatology

References

• Sulzberger MB, Witten VH, Yaffe S, Cortisone acetate administered orally in dermatologic therapy. Arch Dermatol Syphilol (1951) 64: 573–9.
   Google Scholar
• Sulzberger MB, Witten VH, The effect of topically applied Compound F in selected dermatoses. J Invest Dermatol (1952) 19: 101–2. Nesbitt LT Jr, Minimizing complications from systemic glucocorticoid use. Dermatol Clin (1995) 13: 925.
   Google Scholar
• Dutz JP, Ho VC, Immunosuppressive agents in derma- tology. An update. Dermatol Clin (1998) 16(2): 235–51.
   Google Scholar
• Alsberg CL, Black OF, Contribution to the study of maize deterioration. US Dept Agr Plant Industry Bull (1913) 270: 7–48.
   Google Scholar
• Abrams R, Bentley M, Biosynthesis of nucleic acid purines. Biochem Biophys (1959) 79: 91–7.
   Google Scholar
• Abraham EP, The effect of mycophenolic acid on the growth of staphylococcus aureus in heart broth. Biochem J (1945) 39: 398–404.
   Google Scholar
• Cline JC, Nelson JD, Gherzon K et al, In vitro antiviral activity of mycophenolic acid and its reversal by guanine-type compounds. Appl Microbiol (1969) 18: 14–20.
   PubMedGoogle Scholar
• Kosugi Y, Saito Y, Mori S et al, Antiviral activities of mizoribine and other inosine monophosphate dehydro- genase inhibitors against several ortho- and paramyxo- viruses. Antiviral Chem Chemother (1994) 5: 366–71.
   Web of Science ®Google Scholar
• Nelson PH, Eugui E, Wang CC, Allison AC, Synthesis and immunosuppressive activity of some side-chain variants of mycophenolic acid. J Med Chem 33: 833–8.
   Google Scholar
• Jones EL, Epinette WW, Hackney VC et al, Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol (1975) 65: 537–42.
   PubMed Web of Science ®Google Scholar
• Lee WA, Gu L, Miksztal AR et al, Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res (1990) 7: 161–6.
   PubMed Web of Science ®Google Scholar
• Goldblum R, Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheum (1993) 11 (suppl 8): S117–119.
   Google Scholar
• European Mycophenolate Mofetil Cooperative Study Group, Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet (1995) 345: 1321–5.
   Google Scholar
• Sollinger HW, US Renal Transplant Mycophenolate Mofetil Study Group, Mycophenolate mofetil for the prevention of acute rejection in cadaveric renal allograft recipients. Trasnplantation (1995) 60: 225–32.
   Google Scholar
• The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group, A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation (1996) 61: 1029–1037.
   Google Scholar
• Allison AC, Eugui EM, Purine metabolism and the immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant (1996) 10: 77–84.
   PubMed Web of Science ®Google Scholar
• Mehling A, Grabbe S, Voskort M et al, Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol (2000) 165: 2374–81.
   PubMed Web of Science ®Google Scholar
• Physician’s Desk Reference. 55th ed. Montvale, NJ: Medical Economics Company; 2001.
   Google Scholar
• Nousari HC, Sragovich A, Kimyai-Asadi A et al, Mycophenolate mofetil in autoimmune and inflamma- tory skin disorders. J Am Acad Dermatol (1999) 40: 265–268.
   PubMed Web of Science ®Google Scholar
• Geilen CC, Tebbe B, Garcia Bartels C et al, Successful treatment of erythrodermic psoriasis with mycophe- nolate mofetil. Br J Dermatol (1999) 141: 175–6.
   Google Scholar
• Lynch WS, Roenigk HH J, Mycophenolic acid for psoriasis. Arch Dermatol (1977) 113: 1203–8.
   PubMedGoogle Scholar
• Haufs MG, Beissert S, Grabbe S et al, Psoriasis vulgaris treated successfully with mycophenolate mofetil. Br J Dermatol (1998) 138: 179–81.
   PubMed Web of Science ®Google Scholar
• Kirby B, Yates VM, Mycophenoate mofetil for psoriasis. Br J Dermatol (1998) 139(2): 357.
   Google Scholar
• Tong DW, Walder BK, Widespread plaque psoriasis responsive to mycophenolate mofetil. Australasian J Dermatol (1999) 40(3): 135–7.
   Google Scholar
• Grundmann-Kollmann M, Mooser G, Schraeder P et al, Treatment of chronic plaque-stage psoriasis and psor- iatic arthritis with mycophenolate mofetil. J Am Acad Dermatol (2000) 42: 835–7.
   PubMed Web of Science ®Google Scholar
• Davison SC, Morris-Jones R, Powles AV, Fry L, Change of treatment from cyclosporin to mycophenolate mofetil in severe psoriasis. Br J Dermatol (2000) 143: 405–7.
   PubMed Web of Science ®Google Scholar
• Geilen CC, Arnold M, Orfanos CE, Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients. Br J Dermatol (2001) 144(3): 583–6.
   PubMed Web of Science ®Google Scholar
• Geilen CC, Mrowietz U, Lack of efficacy of topical mycophenolic acid in psoriasis vulgaris. J Am Acad Dermatol (2000) 42: 837–40.
   Google Scholar
• Wohlrab J, Jahn K, Plaetzer M et al, Topical application of mycophenolate mofetil in plaque-type psoriasis. Br J Dermatol (2001) 144(6): 1263–4.
   Google Scholar
• Grundmann-Kollmann M, Korting HC, Hehrens S et al, Mychophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol (1999) 40: 957–60.
   PubMed Web of Science ®Google Scholar
• Bredlich RO, Grundmann-Kollmann M, Behrens S et al, Mycophenolate mofetil monotherapy for pemphigus vulgaris. Br J Dermatol (1999) 141: 934.
   PubMed Web of Science ®Google Scholar
• Enk AH, Knop J, Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol (1999) 135: 54–56.
   PubMed Web of Science ®Google Scholar
• Nousari HC, Griffin WA, Anhalt GJ, Successful therapy for bullous pemphigoid with mycophenolate mofetil. J Am Acad Dermatol (1998) 39: 497–8.
   PubMedGoogle Scholar
• Bohm M, Beissert S, Schwartz T et al, Bullous pem- phigoid treated with mycophenolate mofetil. Lancet (1997) 349: 541–2.
   PubMed Web of Science ®Google Scholar
• Katz KH, Marks JG Jr, Helm KF, Pemphigus foliaceus successfully treated with mycophenolate mofetil as a steroid-sparing agent. J Am Acad Dermatol (2000) 42(3): 514–5.
   Google Scholar
• Megahed M, Schmiedeberg S, Becker J, Ruzicka T, Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid-sparing agent. J Am Acad Dermatol (2001) 45(2): 256–9.
   Google Scholar
• Williams JV, Marks JG, Billingsley EM, Use of myco- phenolate mofetil in the treatment of paraneoplastic pemphigus. Br J Dermatol (2000) 142: 506–8.
   PubMed Web of Science ®Google Scholar
• Hsiao CJ, Hsu M, Lee J et al, Paraneoplastic pemphigus in association with a retroperitoneal Castleman’s disease presenting with a lichen planus pemphigoides-like eruption: a case report and review of literature. Br J Dermatol (2001) 144: 372–6.
   Google Scholar
• Schattenkirchner S, Eming S, Hunzelmann N et al, Treatment of epidermolysis bullosa acquisita with myco- phenolate mofetil and autologous keratinocyte grafting. Br J Dermatol 141: 931–55.
   Google Scholar
• Grundmann-Kollmann, Korting HC, Behrens S et al, Successful treatment of severe refractory atopic derma- titis with mycophenolate mofetil. Br J Dermatol (1999) 141: 154–79.
   Google Scholar
• Neuber K, Schwartz I, Itschert G, Dieck AT, Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol (2000) 143: 385–91.
   PubMed Web of Science ®Google Scholar
• Pickenacker A, Luger TA, Schwarz T, Dyshidrotic eczema treated with mycophenolate mofetil. Arch Dermatol (1998) 134: 378–9.
   PubMedGoogle Scholar
• Nousari HC, Anhalt GJ, Morison WL, Mycophenolate in psoralen-UV-A desensitization therapy for chronic acti- nic dermatitis. Arch Dermatol (1999) 135: 1128–9.
   PubMedGoogle Scholar
• Shoji Y, Fukumura T, Kudo M et al, Effect of topical preparation of mycophenolic acid on experimental allergic contact dermatitis of guinea-pigs induced by dinitrofluorobenzene. J Pharm Pharmacol (1994) 46(8): 643–6.
   Google Scholar
• Nousari HC, Goyal S, Anhalt GJ, Successful treatment of resistant hypertrophic and bullous lichen planus with mycophenolate mofetil. Arch Dermatol (1999) 135: 1420–1.
   PubMedGoogle Scholar
• Nousari HC, Lynch W, Anhalt GJ, Petri M, The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum. Arch Dermatol (1998) 134: 1509–11.
   PubMed Web of Science ®Google Scholar
• Hohenleutner U, Mohr VD, Michel S, Landthaler M, Mycophenolate mofetil and cyclosporin treatment for recalcitrant pyoderma gangrenosum. Lancet (1997) 350(9093): 1748.
   Google Scholar
• Gilmour E, Stewart DG, Severe recalcitrant pyoderma gangrenosusm responding to a combination of myco- phenolate mofetil with cyclosporin and complicated by a mononeuritis. Br J Dermatol (2001) 144: 397–400.
   PubMed Web of Science ®Google Scholar
• Wollina U, Karamfilov T, Treatment of recalcitrant ulcers in pyoderma gangrenosum with mycophenolate mofetil and autologous keratinocyte transplantation on a hyaluronic acid matrix. J Eur Acad Dermatol & Venerol (2000) 14(3): 187–90.
   Google Scholar
• Hughes AP, Jackson JM, Callen JP, Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA (2000) 284(12): 1546–8.
   Web of Science ®Google Scholar
• Fickert P, Hinterleitner TA, Wenzl HH et al, Mycophe- nolate mofetil in patients with Crohn’s disease. Am J Gastroenterol (1998) 93: 2529–32.
   PubMed Web of Science ®Google Scholar
• Altschuler EL, Mycophenolate mofetil, Crohn’s disease, measles? Am J Gastroenterol (2000) 95(2): 550–1.
   Google Scholar
• Ruiz-Irastorza G, Khamashta MA, Hughes GR, Therapy of systemic lupus erythematosus: new agents and new evidence. Expert Opin Investig Drugs (2000) 9: 1581–93.
   PubMed Web of Science ®Google Scholar
• Gaubitz M, Schorat A, Schotte H et al, Mycophenolate mofetil for the treatment of systemic lupus erythemato- sus: an open pilot trial. Lupus (1999) 8: 731–6.
   PubMed Web of Science ®Google Scholar
• Schanz S, Ulmer A, Rassner G, Fierlbeck G, Successful treatment of subacute lupus erythematosus with mycophenolate mofetil. Br J Dermatol (2002) 147(1): 174–8.
   Google Scholar
• Gelber AC, Nousari HC, Wigley FM, Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of four cases. J Rheumatol (2000) 27: 1542–5.
   PubMed Web of Science ®Google Scholar
• Daina E, Schneppati A, Renuzzi G, Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases. Ann Int Med (1999) 130: 422–6.
   Google Scholar
• Nowack R, Birck R, van der Woude FJ, Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet (1997) 349: 774.
   PubMed Web of Science ®Google Scholar
• Worm M, Sterry W, Olde G, Mycophenolate mofetil is effective for maintenance therapy of hypocomplemen- taeimic urticarial vasculitis. Br J Dermatol (2000) 143(6): 1324.
   Google Scholar
• Nowack R, Gobel U, Klooker P et al, Mycophenolate mofetil for maintenance therapy of Wegeners’ granulo- matosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol (1999) 10(9): 1965–71.
   PubMed Web of Science ®Google Scholar
• Basara N, Kiehl MG, Blau W et al, Mycophenolate mofetil in the treatment of acute and chronic GVHD in hematopietic stem cell transplant patients: four years of experience. Transplantation Proceedings (2001) 33(3): 2121–3.
   Google Scholar
• Busca A, Saroglia EM, Lanino E et al, Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplan- tation. Bone Marrow Transplant (2000) 25: 1067–71.
   PubMed Web of Science ®Google Scholar
• Grundmann-Kollmann M, Behrens S, Gruss C et al, Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy. J Am Acad Dermatol (2000) 42: 134–6.
   Google Scholar
• Kouba DJ, Mimouni D, Rencic A, Nousari HC, Myco- phenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Br J Dermatol (2003) 148: 147–8.
   PubMed Web of Science ®Google Scholar
• Epinette WW, Parker CM, Jones EL, Greist MC, Mycophenolic acid for psoriasis: a review of pharmacol- ogy, long-term efficacy, and safety. J Am Acad Dermatol (1987) 17: 962–71.
   PubMed Web of Science ®Google Scholar
• US Renal Transplant Mycophenolate Mofetil Study Group, Mycophenolate mofetil in cadaveric renal transplantation. Am J Kidney Dis (1999) 34(2): 296–303.
   Google Scholar
• Mathew TH, Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group, A blinded, long- term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Transplantation (1998) 65(11): 1450–4.
   PubMed Web of Science ®Google Scholar
• European Mycophenolate Moeftil Cooperative Study Group, Mycophenolate mofetil in renal transplantation: three-year results from the placebo-controlled trial. Transplantation (1999) 68(3): 391–6.
   PubMedGoogle Scholar
• Silvermann Kitchin JE, Pomeranz MK, Pak G et al, Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. J Am Acad Dermatol (1997) 37: 445–9.
   Google Scholar
• Jones JW Jr, Ustuner ET, Zdichavsky M et al, Long-term survival of an extremity composite tissue allograft with FK506-mycophenolate mofetil therapy. Surgery (1999) 126: 384–8.
   Google Scholar
• Neyts J, DeClercq E, Mycophenolate mofetil strongly potentiates the anti-herpes virus activity of acyclovir. Antiviral Res (1998) 40: 53–6.
   PubMed Web of Science ®Google Scholar
• Sollinger HW, Belzer FO, Deierhoi MH et al, RS-61443 (Mycophenolate mofetil): a multicenter study for refrac- tory kidney transplant rejection. Ann Surg (1992) 216: 513–9.
   PubMedGoogle Scholar
• Paterson DL, Singh N, Panebianco A et al, Infectious complications occurring in liver transplant recipients receiving mycophenolate mofetil. Transplantation (1998) 66(5): 593–8.
   Google Scholar
• Rostaing L, Izopet J, Sandres K et al, Changes in hepatitis C virus RNA viremia concentrations in long- term renal transplant patients after introduction on mycophenolate mofetil. Transplantation (2000) 69(5): 991–4.
   Google Scholar
• Chapuis AG, Paolo RG, D’Agostino C et al, Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med (2000) 6: 762–8.
   PubMedGoogle Scholar
• Ensley RD, Bristow MR, Olsen SL et al, The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation (1993) 56: 75–82.
   PubMed Web of Science ®Google Scholar
• Semhoun-Ducloux S, Ducloux D, Miguet JP, Myco- phenophenolate mofetil-induced dyshidrotic eczema. Ann Int Med (2000) 132: 417.
   PubMedGoogle Scholar